Zurcher Kantonalbank Zurich Cantonalbank trimmed its stake in shares of Evotec SE (NASDAQ:EVO – Free Report) by 13.9% during the fourth quarter, HoldingsChannel reports. The fund owned 174,266 shares of the company’s stock after selling 28,102 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Evotec were worth $2,037,000 as of its most recent SEC filing.
Analysts Set New Price Targets
A number of research analysts recently weighed in on EVO shares. Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a research report on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a “hold” rating to a “buy” rating in a research report on Friday, April 12th.
Get Our Latest Stock Analysis on Evotec
Evotec Stock Up 3.9 %
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Featured Articles
- Five stocks we like better than Evotec
- The How And Why of Investing in Oil Stocks
- Charles Schwab Fortifies its Uptrend on EPS Beat
- What is the S&P/TSX Index?
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What is the Hang Seng index?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Want to see what other hedge funds are holding EVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evotec SE (NASDAQ:EVO – Free Report).
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.